Influenza (seasonal)

New Products Push Influenza Vaccine Market Above $3billion

A new report out from Kalorama Information estimates that influenza vaccines sales rose by 13% to $3.1 billion in 2013. This figure brings the influenza vaccines market up from $2.8 billion in 2012, and back to the sort of levels we saw before the government’s stockpiling 2010 -as a result of this stockpiling, and perhaps over purchasing, the market dropped by 30% in 2011.

Infographic: The Next Great Pandemic

Take a look at these informative infographics on TB, Cholera, HIV, pneumonia, and antimicrobal-resistant diseases from the 


Fludase - Experimental Antiviral Drug for Influenza

NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181), an innovative, recombinant drug for the treatment and prevention of influenza.
Fludase completed its initial preclinical development and entered clinical development to determine its efficacy and safety in humans.
In preclinical studies, Fludase displayed potent antiviral activity against clinical influenza isolates, including isolates of the deadly H5N1 strain of avian influenza.

Public health: Joint purchasing of vaccines and medicines becomes a reality in the EU

Today, the Commission approved a Joint Procurement Agreement, which will enable all EU countries to procure pandemic vaccines and other medical countermeasures as a group, rather than individually.

Fineberg: 5 years after H1N1, world still not ready for pandemic

Five years after the 2009 H1N1 influenza virus emerged, the world's ability to cope with a flu pandemic is a bit better than it was in April 2009, but there's still a long way to go, says Harvey Fineberg, MD, PhD, who chaired the international committee that was assigned by the World Health Organization (WHO) to evaluate the global response to the pandemic.


Tamiflu Reduced Risk of Death by 25% in Patients Hospitalised with H1N1

A meta-analysis published online today in The Lancet Respiratory Medicine has concluded that patients admitted to hospital


CDC: Flu vaccination cuts children's risk for intensive care hospitalization Read more: CDC: Flu vaccination cuts children's risk for intensive care hospitalization

Though the flu season has already peaked and is nearly over, the Centers for Disease Control and Prevention (CDC) still recommends that people get vaccinated if they have not done so this season, because flu virus activity can continue as late as May.
In fact, flu vaccines reduce a child's risk of intensive care hospitalization related to the flu by 74%, according to a CDC study published recently in the Journal of Infectious Diseases.

Mutations during vaccine making weakened last year's flu jab Read more: Mutations during vaccine making weakened last year's flu jab

Last year's flu vaccine didn't provide as much coverage as scientists had hoped, and now researchers from Canada's British Columbia Centre for Disease Control think they have discovered the culprit.